Entropy Neurodynamics Limited has released a press release.
Development Program Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Entropy Neurodynamics Limited on 6ix
Earlier from Entropy Neurodynamics
- Appointment of Chief Commercial Officer
- Appendix 4C - quarterly
- Appendix 4E and Annual Financial Report FY 2019
- PLEXOVAL Exosome Wound Healing Human Study Starts
- Share Purchase Plan 2019 Offer Document
Later from Entropy Neurodynamics
- Key Management Contracts Extended
- First Dosing in PLEXOVAL Exosome Wound Healing Human Study
- December Quarterly Report and Appendix 4C
- Independent Plexaris and Cevaris testing
- Cevaris testing shows positive results in models of ED
Follow Entropy Neurodynamics into a list and get an email when it puts out news.
Follow Entropy Neurodynamics